| 國立成功大學 |
2021 |
Factors associated with treatment failure of direct-acting antivirals for chronic hepatitis C: A real-world nationwide hepatitis C virus registry programme in Taiwan
|
Chen, Chen C.-Y.;Huang, C.-F.;Cheng, P.-N.;Tseng, K.-C.;Lo, C.-C.;Kuo, H.-T.;Huang, Y.-H.;Tai, C.-M.;Peng, C.-Y.;Bair, M.-J.;Chen, Chen C.-H.;Yeh, M.-L.;Lin, C.-L.;Lin, C.-Y.;Lee, P.-L.;Chong, L.-W.;Hung, C.-H.;Huang, J.-F.;Yang, C.-C.;Hu, J.-T.;Lin, C.-W.;Chen, Chen C.-T.;Wang, C.-C.;Su, W.-W.;Hsieh, T.-Y.;Lin, C.-L.;Tsai, W.-L.;Lee, T.-H.;Chen, G.-Y.;Wang, S.-J.;Chang, Chang C.-C.;Mo, L.-R.;Yang, S.-S.;Wu, Wu W.-C.;Huang, C.-S.;Hsiung, C.-K.;Kao, C.-N.;Tsai, P.-C.;Liu, C.-H.;Lee, M.-H.;Liu, C.-J.;Dai, C.-Y.;Kao, J.-H.;Chuang, W.-L.;Lin, H.-C.;Yu, M.-L. |
| 國立成功大學 |
2021 |
Drug resistance profile and clinical features for hepatitis C patients experiencing DAA failure in Taiwan
|
Hong, C.-M.;Lin, Y.-Y.;Liu, C.-J.;Lai, Y.-Y.;Yeh, S.-H.;Yang, H.-C.;Kao, J.-H.;Hsu, S.-J.;Huang, Y.-H.;Yang, S.-S.;Kuo, H.-T.;Cheng, P.-N.;Yu, M.-L.;Chen, P.-J. |
| 國立成功大學 |
2021 |
Submillisecond Laser Annealing Induced Surface and Subsurface Restructuring of Cu-Ni-Pd Trimetallic Nanocatalyst Promotes Thermal CO2Reduction
|
Bhalothia, D.;Hsiung, W.-H.;Yang, S.-S.;Yan, C.;Chen, P.-C.;Lin, T.-H.;Wu, S.-C.;Chen, P.-C.;Wang, K.-W.;Lin, M.-W.;Chen, T.-Y. |
| 臺大學術典藏 |
2020-12-30T02:43:25Z |
IL-10 promoter gene polymorphisms and sustained response to combination therapy in Taiwanese chronic hepatitis C patients
|
Hsieh Y.Y.; Lu Y.T.; Chuang J.Y.; Yang S.S.; Chen C.Y.; SHAN-CHWEN CHANG; Chang C.S.; Yeh H.Z.; Kao J.H. |
| 臺大學術典藏 |
2020-12-29T05:33:52Z |
Generic sofosbuvir-based interferon-free direct acting antiviral agents for patients with chronic hepatitis C virus infection: a real-world multicenter observational study
|
Yang S.-S.; Liu C.-H.; Huang Y.-J.; Liu C.-H.;Huang Y.-J.;Yang S.-S.;Chang C.-H.;Yang S.-S.;Hsin-Yun Sun;Liu C.-J.;Liu W.-C.;Su T.-H.;Yang H.-C.;Hong C.-M.;Tseng T.-C.;Chen P.-J.;Chen D.-S.;Hung C.-C.;Kao J.-H.; Kao J.-H.; Hung C.-C.; Chen D.-S.; Chang C.-H.; Yang S.-S.; HSIN-YUN SUN; Liu C.-J.; Liu W.-C.; Su T.-H.; Yang H.-C.; Hong C.-M.; Tseng T.-C.; Chen P.-J. |
| 臺大學術典藏 |
2020-12-28T08:14:10Z |
Management consensus guideline for hepatocellular carcinoma: 2016 updated by the Taiwan Liver Cancer Association and the Gastroenterological Society of Taiwan
|
Chen C.-H.; Dai C.-Y.; Wang T.-E.; Su C.-W.; Wang J.-H.; Lu S.-N.; Lu S.-N.;Wang J.-H.;Su C.-W.;Wang T.-E.;Dai C.-Y.;Chen C.-H.;Chen R.-C.;Yang S.-S.;Hung C.-F.;Huang S.-F.;Liao L.-Y.;Huo T.-I.;Wu C.-C.;Lee P.-H.;Ting C.-T.;Lee W.-C.;Chau G.-Y.;Wang C.-C.;Lee K.-T.;Huang Y.-H.;Ho M.-C.;Lin S.-M.;Huang G.-T.;Chen K.-Y.;Lin X.-Z.;Hwang J.-I.;Chiou Y.-Y.;Wang C.-K.;Hu J.-T.;Chen S.-C.;Liang P.-C.;Lee R.-C.;Wu D.-K.;Lin C.-Y.;Lin C.-C.;Cheng A.-L.;Hsu C.;Chao Y.;Chen L.-T.;Wang P.-M.;Wang P.-M.;Hong J.-H.;Hsu H.-C.;Chen S.-W.;Leung S.W.;Cheng J.C.-H.;Wu J.-C.;Wu C.-Y.;Hsu Y.-C.;Hsu C.-W.;Yen-Hsuan Ni;Lin C.-L.;Local Ablation Group, Surveillance Group, Diagnosis Group, Staging Group, Surgery Group, Tace/Tare/Hai Group, Target Therapy/Systemic Therapy Group, Radiotherapy Group, Prevention Group, Drafting Group; Wang P.-M.; Chao Y.; Chen L.-T.; Hsu C.; Cheng A.-L.; Lin C.-C.; Ho M.-C.; Lin S.-M.; Huang G.-T.; Chen K.-Y.; Lin X.-Z.; Hwang J.-I.; Chiou Y.-Y.; Wang C.-K.; Hu J.-T.; Chen S.-C.; Liang P.-C.; Lee R.-C.; Wu D.-K.; Lin C.-Y.; Chen R.-C.; Yang S.-S.; Hung C.-F.; Huang S.-F.; Liao L.-Y.; Huo T.-I.; Wu C.-C.; Lee P.-H.; Ting C.-T.; Lee W.-C.; Chau G.-Y.; Wang C.-C.; Lee K.-T.; Huang Y.-H.; Wang P.-M.; Hong J.-H.; Hsu H.-C.; Chen S.-W.; Leung S.W.; Cheng J.C.-H.; Wu J.-C.; Wu C.-Y.; Hsu Y.-C.; Hsu C.-W.; YEN-HSUAN NI; Lin C.-L.; Local ablation group, Surveillance group, Diagnosis group, Staging group, Surgery group, TACE/TARE/HAI group, Target therapy/systemic therapy group, Radiotherapy group, Prevention group, Drafting group |
| 臺大學術典藏 |
2020-12-18T05:28:42Z |
A pharmaco-economic evaluation of deferasirox for treating patients with iron overload caused by transfusion-dependent thalassemia in Taiwan
|
Lin K.-H.; Lin D.-T.; Yang Y.-L.; HSIU-HAO CHANG; Jou S.-T.; Lu M.-Y.; Yang S.-S.; Ho W.-L.; Chung K.-P. |
| 臺大學術典藏 |
2020-12-16T07:21:55Z |
A pharmaco-economic evaluation of deferasirox for treating patients with iron overload caused by transfusion-dependent thalassemia in Taiwan
|
Ho W.-L.; Chung K.-P.; Yang S.-S.; MENG-YAO LU; Jou S.-T.; Chang H.-H.; Yang Y.-L.; Lin D.-T.; Lin K.-H. |
| 臺大學術典藏 |
2020-11-19T03:19:55Z |
Heparanase inhibitor PI-88 as adjuvant therapy for hepatocellular carcinoma after curative resection: A randomized phase II trial for safety and optimal dosage
|
Liu C.-J.; PO-HUANG LEE; Lin D.-Y.; Wu C.-C.; Jeng L.-B.; Lin P.-W.; Mok K.-T.; Lee W.-C.; Yeh H.-Z.; Ho M.-C.; Yang S.-S.; Lee C.-C.; Yu M.-C.; Hu R.-H.; Peng C.-Y.; Lai K.-L.; Chang S.S.-C.; Chen P.-J. |
| 臺大學術典藏 |
2020-11-19T03:19:31Z |
Heavy alcohol consumption increases the incidence of hepatocellular carcinoma in hepatitis B virus-related cirrhosis
|
Lin C.-W.; Lin C.-C.; Mo L.-R.; Chang C.-Y.; Perng D.-S.; Hsu C.-C.; Lo G.-H.; Chen Y.-S.; Yen Y.-C.; Hu J.-T.; Yu M.-L.; PO-HUANG LEE; Lin J.-T.; Yang S.-S. |
| 臺大學術典藏 |
2020-11-19T03:19:23Z |
Adjuvant heparanase inhibitor PI-88 therapy for hepatocellular carcinoma recurrence
|
Lin Y.-J.; Mok K.-T.; Lee W.-C.; Yeh H.-Z.; Ho M.-C.; Yang S.-S.; Yang M.-D.; Yu M.-C.; Hu R.-H.; Peng C.-Y.; Lai K.-L.; Chang S.S.-C.; Chen P.-J.; Liu C.-J.; Chang J.; PO-HUANG LEE; Lin D.-Y.; Wu C.-C.; Jeng L.-B. |
| 臺大學術典藏 |
2020-11-03T08:19:41Z |
Glecaprevir/pibrentasvir for patients with chronic hepatitis C virus infection and severe renal impairment
|
Kao J.-H.; Chen D.-S.; Chen P.-J.; Tseng T.-C.; Su T.-H.; Liu C.-J.; CHEN-HUA LIU; Yang S.-S.; Peng C.-Y.; Lin W.-T. |
| 臺大學術典藏 |
2020-11-03T08:19:40Z |
High Risk of Clinical Relapse in Patients With Chronic Hepatitis B Virus Infection After Cessation of Prophylactic Antiviral Therapy for Rituximab-Containing Chemotherapy
|
Chang W.-Y.; Chiu Y.-C.; Chiu F.-W.; Hsu Y.-C.; Tseng T.-C.; Cheng P.-N.; Yang S.-S.; Liu C.-J.; Su T.-H.; Yang H.-C.; CHEN-HUA LIU; Chen P.-J.; Chen D.-S.; Kao J.-H. |
| 臺大學術典藏 |
2020-11-03T08:19:39Z |
Elbasvir/grazoprevir for hepatitis C virus genotype 1b East-Asian patients receiving hemodialysis
|
CHEN-HUA LIU; Peng C.-Y.; Fang Y.-J.; Kao W.-Y.; Yang S.-S.; Lin C.-K.; Lai H.-C.; Su W.-P.; Fang S.-U.; Chang C.-C.; Su T.-H.; Liu C.-J.; Chen P.-J.; Chen D.-S.; Kao J.-H. |
| 臺大學術典藏 |
2020-10-14T07:24:43Z |
Reduced toll-like receptor 9 expression on peripheral C D14+ monocytes of chronic hepatitis B patients and its restoration by effective therapy
|
Kao J.-H.; Yang S.-S.; Huang Y.-W.; Hsu C.-K.; Lin S.-C.; SHU-CHEN WEI; Hu J.-T.; Chang H.-Y.; Liang C.-W.; Chen D.-S.; Chen P.-J.; Hsu P.-N. |
| 臺大學術典藏 |
2020-09-30T03:22:22Z |
Generic sofosbuvir-based interferon-free direct acting antiviral agents for patients with chronic hepatitis C virus infection: a real-world multicenter observational study
|
Liu C.-H.; Huang Y.-J.; Yang S.-S.; Chang C.-H.; Yang S.-S.; Sun H.-Y.; Liu C.-J.; Liu W.-C.; Su T.-H.; Yang H.-C.; Hong C.-M.; Tseng T.-C.; Chen P.-J.; Chen D.-S.; CHIEN-CHING HUNG; Kao J.-H. |
| 臺大學術典藏 |
2020-08-11T08:36:42Z |
Management consensus guideline for hepatocellular carcinoma: 2016 updated by the Taiwan Liver Cancer Association and the Gastroenterological Society of Taiwan
|
Chiou Y.-Y.; Wang C.-K.; Hu J.-T.; Chen S.-C.; PO-CHIN LIANG; Lee R.-C.; Wu D.-K.; Lin C.-Y.; Lin C.-C.; Cheng A.-L.; Hsu C.; Chao Y.; Chen L.-T.; Wang P.-M.; Wang P.-M.; Hong J.-H.; Hsu H.-C.; Chen S.-W.; Leung S.W.; Cheng J.C.-H.; Wu J.-C.; Wu C.-Y.; Hsu Y.-C.; Hsu C.-W.; Ni Y.-H.; Lin C.-L.; Local ablation group, Surveillance group, Diagnosis group, Staging group, Surgery group, TACE/TARE/HAI group, Target therapy/systemic therapy group, Radiotherapy group, Prevention group, Drafting group; Wu C.-C.; Lee P.-H.; Ting C.-T.; Lee W.-C.; Chau G.-Y.; Wang C.-C.; Lee K.-T.; Huang Y.-H.; Ho M.-C.; Lin S.-M.; Huang G.-T.; Chen K.-Y.; Lin X.-Z.; Hwang J.-I.; Lu S.-N.;Wang J.-H.;Su C.-W.;Wang T.-E.;Dai C.-Y.;Chen C.-H.;Chen R.-C.;Yang S.-S.;Hung C.-F.;Huang S.-F.;Liao L.-Y.;Huo T.-I.;Wu C.-C.;Lee P.-H.;Ting C.-T.;Lee W.-C.;Chau G.-Y.;Wang C.-C.;Lee K.-T.;Huang Y.-H.;Ho M.-C.;Lin S.-M.;Huang G.-T.;Chen K.-Y.;Lin X.-Z.;Hwang J.-I.;Chiou Y.-Y.;Wang C.-K.;Hu J.-T.;Chen S.-C.;Po-Chin Liang;Lee R.-C.;Wu D.-K.;Lin C.-Y.;Lin C.-C.;Cheng A.-L.;Hsu C.;Chao Y.;Chen L.-T.;Wang P.-M.;Wang P.-M.;Hong J.-H.;Hsu H.-C.;Chen S.-W.;Leung S.W.;Cheng J.C.-H.;Wu J.-C.;Wu C.-Y.;Hsu Y.-C.;Hsu C.-W.;Ni Y.-H.;Lin C.-L.;Local Ablation Group, Surveillance Group, Diagnosis Group, Staging Group, Surgery Group, Tace/Tare/Hai Group, Target Therapy/Systemic Therapy Group, Radiotherapy Group, Prevention Group, Drafting Group; Huo T.-I.; Liao L.-Y.; Wang J.-H.; Su C.-W.; Wang T.-E.; Dai C.-Y.; Chen C.-H.; Chen R.-C.; Yang S.-S.; Hung C.-F.; Huang S.-F.; Lu S.-N. |
| 臺大學術典藏 |
2020-06-22T07:37:12Z |
SPAK-knockout mice manifest Gitelman syndrome and impaired vasoconstriction
|
Yang S.-S.;Lo Y.-F.;Wu C.-C.;Shu-Wha Lin;Yeh C.-J.;Chu P.;Sytwu H.-K.;Uchida S.;Sasaki S.;Lin S.-H.; Yang S.-S.; Lo Y.-F.; Wu C.-C.; SHU-WHA LIN; Yeh C.-J.; Chu P.; Sytwu H.-K.; Uchida S.; Sasaki S.; Lin S.-H. |
| 臺大學術典藏 |
2020-06-22T07:37:11Z |
Severe metabolic acidosis causes early lethality in NBC1 W516X knock-in mice as a model of human isolated proximal renal tubular acidosis
|
Lo Y.-F.;Yang S.-S.;Seki G.;Yamada H.;Horita S.;Yamazaki O.;Fujita T.;Usui T.;Tsai J.-D.;Yu I.-S.;Shu-Wha Lin;Lin S.-H.; Lo Y.-F.; Yang S.-S.; Seki G.; Yamada H.; Horita S.; Yamazaki O.; Fujita T.; Usui T.; Tsai J.-D.; Yu I.-S.; SHU-WHA LIN; Lin S.-H. |
| 臺大學術典藏 |
2020-06-22T07:37:09Z |
Impaired phosphorylation of Na +-K +-2Cl - cotransporter by oxidative stress-responsive kinase-1 deficiency manifests hypotension and Bartter-like syndrome
|
Lin S.-H.;Yu I.-S.;Jiang S.-T.;Shu-Wha Lin;Chu P.;Chen A.;Sytwu H.-K.;Sohara E.;Uchida S.;Sasaki S.;Yang S.-S.; Lin S.-H.; Yu I.-S.; Jiang S.-T.; SHU-WHA LIN; Chu P.; Chen A.; Sytwu H.-K.; Sohara E.; Uchida S.; Sasaki S.; Yang S.-S. |
| 臺大學術典藏 |
2020-04-27T08:45:07Z |
Management consensus guideline for hepatocellular carcinoma: 2016 updated by the Taiwan Liver Cancer Association and the Gastroenterological Society of Taiwan
|
Huang Y.-H.; Lee K.-T.; Wang C.-C.; Chau G.-Y.; Lee W.-C.; Ting C.-T.; Lee P.-H.; Wu C.-C.; Huo T.-I.; Liao L.-Y.; Huang S.-F.; Hung C.-F.; Yang S.-S.; Chen R.-C.; Chen C.-H.; Dai C.-Y.; Wang T.-E.; Su C.-W.; Wang J.-H.; Lu S.-N.;Wang J.-H.;Su C.-W.;Wang T.-E.;Dai C.-Y.;Chen C.-H.;Chen R.-C.;Yang S.-S.;Hung C.-F.;Huang S.-F.;Liao L.-Y.;Huo T.-I.;Wu C.-C.;Lee P.-H.;Ting C.-T.;Lee W.-C.;Chau G.-Y.;Wang C.-C.;Lee K.-T.;Huang Y.-H.;Ho M.-C.;Lin S.-M.;Huang G.-T.;Chen K.-Y.;Lin X.-Z.;Hwang J.-I.;Chiou Y.-Y.;Wang C.-K.;Hu J.-T.;Chen S.-C.;Liang P.-C.;Lee R.-C.;Wu D.-K.;Lin C.-Y.;Lin C.-C.;Cheng A.-L.;Hsu C.;Chao Y.;Chen L.-T.;Wang P.-M.;Wang P.-M.;Hong J.-H.;Hsu H.-C.;Chen S.-W.;Leung S.W.;Chia-Hsien Cheng;Wu J.-C.;Wu C.-Y.;Hsu Y.-C.;Hsu C.-W.;Ni Y.-H.;Lin C.-L.;Local Ablation Group, Surveillance Group, Diagnosis Group, Staging Group, Surgery Group, Tace/Tare/Hai Group, Target Therapy/Systemic Therapy Group, Radiotherapy Group, Prevention Group, Drafting Group; Lu S.-N.; Ho M.-C.; Lin S.-M.; Huang G.-T.; Chen K.-Y.; Lin X.-Z.; Hwang J.-I.; Chiou Y.-Y.; Wang C.-K.; Hu J.-T.; Chen S.-C.; Liang P.-C.; Lee R.-C.; Wu D.-K.; Lin C.-Y.; Lin C.-C.; Cheng A.-L.; Hsu C.; Chao Y.; Chen L.-T.; Wang P.-M.; Wang P.-M.; Hong J.-H.; Hsu H.-C.; Chen S.-W.; Leung S.W.; CHIA-HSIEN CHENG; Wu J.-C.; Wu C.-Y.; Hsu Y.-C.; Hsu C.-W.; Ni Y.-H.; Lin C.-L.; Local ablation group, Surveillance group, Diagnosis group, Staging group, Surgery group, TACE/TARE/HAI group, Target therapy/systemic therapy group, Radiotherapy group, Prevention group, Drafting group |
| 臺大學術典藏 |
2020-03-17T07:49:26Z |
Classification of PICO elements by text features systematically extracted from PubMed abstracts
|
Huang K.-C.; Liu C.C.-H.; Yang S.-S.; FU-REN XIAO; Wong J.-M.; Liao C.-C.; Chiang I.-J. |
| 臺大學術典藏 |
2020-02-19T09:33:57Z |
Heparanase inhibitor PI-88 as adjuvant therapy for hepatocellular carcinoma after curative resection: A randomized phase II trial for safety and optimal dosage
|
Liu C.-J.; Lee P.-H.; Lin D.-Y.; Wu C.-C.; Jeng L.-B.; Lin P.-W.; Mok K.-T.; Lee W.-C.; Yeh H.-Z.; MING-CHIH HO; Yang S.-S.; Lee C.-C.; Yu M.-C.; Hu R.-H.; Peng C.-Y.; Lai K.-L.; Chang S.S.-C.; Chen P.-J. |
| 臺大學術典藏 |
2020-02-19T09:33:45Z |
Adjuvant heparanase inhibitor PI-88 therapy for hepatocellular carcinoma recurrence
|
Chen P.-J.; Chang S.S.-C.; Lai K.-L.; Peng C.-Y.; Hu R.-H.; Yu M.-C.; Yang M.-D.; Yang S.-S.; MING-CHIH HO; Liu C.-J.; Chang J.; Lee P.-H.; Lin D.-Y.; Wu C.-C.; Jeng L.-B.; Lin Y.-J.; Mok K.-T.; Lee W.-C.; Yeh H.-Z. |
| 臺大學術典藏 |
2020-02-19T09:33:41Z |
Management consensus guideline for hepatocellular carcinoma: 2016 updated by the Taiwan Liver Cancer Association and the Gastroenterological Society of Taiwan
|
Lu S.-N.;Wang J.-H.;Su C.-W.;Wang T.-E.;Dai C.-Y.;Chen C.-H.;Chen R.-C.;Yang S.-S.;Hung C.-F.;Huang S.-F.;Liao L.-Y.;Huo T.-I.;Wu C.-C.;Lee P.-H.;Ting C.-T.;Lee W.-C.;Chau G.-Y.;Wang C.-C.;Lee K.-T.;Huang Y.-H.;Ming-Chih Ho;Lin S.-M.;Huang G.-T.;Chen K.-Y.;Lin X.-Z.;Hwang J.-I.;Chiou Y.-Y.;Wang C.-K.;Hu J.-T.;Chen S.-C.;Liang P.-C.;Lee R.-C.;Wu D.-K.;Lin C.-Y.;Lin C.-C.;Cheng A.-L.;Hsu C.;Chao Y.;Chen L.-T.;Wang P.-M.;Wang P.-M.;Hong J.-H.;Hsu H.-C.;Chen S.-W.;Leung S.W.;Cheng J.C.-H.;Wu J.-C.;Wu C.-Y.;Hsu Y.-C.;Hsu C.-W.;Ni Y.-H.;Lin C.-L.;Local Ablation Group;Surveillance Group;Diagnosis Group;Staging Group;Surgery Group;Tace/Tare/Hai Group;Target Therapy/Systemic Therapy Group;Radiotherapy Group;Prevention Group;Drafting Group; Lu S.-N.; Wang J.-H.; Su C.-W.; Wang T.-E.; Dai C.-Y.; Chen C.-H.; Chen R.-C.; Yang S.-S.; Hung C.-F.; Huang S.-F.; Liao L.-Y.; Huo T.-I.; Wu C.-C.; Lee P.-H.; Ting C.-T.; Lee W.-C.; Chau G.-Y.; Wang C.-C.; Lee K.-T.; Huang Y.-H.; MING-CHIH HO; Lin S.-M.; Huang G.-T.; Chen K.-Y.; Lin X.-Z.; Hwang J.-I.; Chiou Y.-Y.; Wang C.-K.; Hu J.-T.; Chen S.-C.; Liang P.-C.; Lee R.-C.; Wu D.-K.; Lin C.-Y.; Lin C.-C.; Cheng A.-L.; Hsu C.; Chao Y.; Chen L.-T.; Wang P.-M.; Hong J.-H.; Hsu H.-C.; Chen S.-W.; Leung S.W.; Cheng J.C.-H.; Wu J.-C.; Wu C.-Y.; Hsu Y.-C.; Hsu C.-W.; Ni Y.-H.; Lin C.-L.; Local ablation group; Surveillance group; Diagnosis group; Staging group; Surgery group; TACE/TARE/HAI group; Target therapy/systemic therapy group; Radiotherapy group; Prevention group; Drafting group |
